Spineart USA Inc
$830.2K 1,361 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Next Science LLC
Next Science LLC reported $829,878.35 across General Payments, Research, and Ownership to 1,698 physicians and teaching hospitals across 1,710 transactions.
- $829.9K Above-median payer
- All-tracks total
- 1,710 Top quartile volume
- Transactions
- 1,698 Top quartile reach
- Recipients
- +$393.0K
- General Payments vs PY2023
Next Science LLC reported $829,878.35 across all CMS Open Payments tracks (General + Research + Ownership) to 1,698 physicians and teaching hospitals in Program Year 2024 - ranking #664 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $546,356.47, averaging $488.74 per recipient.
How Next Science LLC's $829.9K all-tracks total breaks down
Next Science LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
22/100
Total payments
F
18/100
Transaction volume
F
22/100
Physician reach
F
23/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer next-science-llc Next Science LLC
$829.9K · #664/1,925 · 0.0% industry · PY2024
- TOT $829.9K
- RANK #664
- SHARE 0.0%
- TXN 1,710
- RCP 1,698
- CAT 2
- GEN $546.4K
- ΔGEN +$393.0K
- TOP1 34.5%
- PY 2024
Volume peers
Nearest volume peer: Spineart USA Inc ($830.2K)
Next Science LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Next Science LLC's CMS-reported General Payments increased by $393.0K (+256.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NEXT SCIENCE LLCPY2023: NEXT SCIENCE LLCPY2024: Next Science LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $153,340.01
- PY2024
- $546,356.47
What the Data Shows for Next Science LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Next Science LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $471.4K across 169 transactions, 86.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Next Science LLC made 2 types of general payments. "Consulting Fee" is the largest category at $471.4K, 86.3% of General Payments.
How Next Science LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $471.4K | 169 | 86.3% |
| Food and Beverage | $75.0K | 1,529 | 13.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $468,003.31 (85.7%) of $546,356.47 in this company's General Payments records across 884 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Next Science LLC
The five named recipients with the highest reported General Payments from this company
- 1
Patricia Stevenson
$188,353.68 across 41 reported transactions
- 2
Jon Minter
$180,341.22 across 17 reported transactions
- 3
Matthew Regulski
$91,346.32 across 51 reported transactions
- 4
Andrew Wickline
$6,000.00 across 2 reported transactions
- 5
Berdj Stepanian
$1,962.09 across 50 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Next Science LLC's spend rank (#664 of 1,925, top 34% by spend) and concentration rank (#637 of 1,838, top 35% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Fennec Pharmaceuticals, Inc. : $215.0K total payments, HHI 2615
- Tulsa Dental Products LLC : $2.7M total payments, HHI 2613
- MIS Implants Technologies, Inc. : $56.4K total payments, HHI 2592
- Atrium Medical Corporation : $13.1K total payments, HHI 2591
- DeGen Medical, Inc. : $324.9K total payments, HHI 2579
- Nutech Spine, Inc. : $22.0K total payments, HHI 2564
- Next Science LLC (this company) : $546.4K total payments, HHI 2560
- FEMSelect Inc. : $65.2K total payments, HHI 2552
- Skye Orthobiologics LLC : $7.2M total payments, HHI 2533
- Aidoc Medical Ltd : $83.5K total payments, HHI 2529
- Boehringer Ingelheim RCV GmbH & Co KG : $63.7K total payments, HHI 2525
- Oxford Performance Materials, Inc. : $21.8K total payments, HHI 2520
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Next Science LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Next Science LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Next Science LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Spine Wave, Inc.
$825.7K 509 recipients
Compare payment profiles
Vertos Medical, Inc.
$836.6K 6,652 recipients
Compare payment profiles
Genesys Orthopedics Systems, L.L.C.
$837.2K 550 recipients
Compare payment profiles
Provepharm Inc.
$837.3K 117 recipients
Compare payment profiles
Kardium Inc.
$816.9K 0 recipients
Compare payment profiles
Put this to use
Next Science LLC ranks #664 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Next Science LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.